A review of dolutegravir-associated weight gain and secondary metabolic comorbidities

被引:2
|
作者
Jemal, Mohammed [1 ]
机构
[1] Debre Markos Univ, Sch Med, Dept Biomed Sci, POB 269, Debre Markos, Amhara, Ethiopia
来源
SAGE OPEN MEDICINE | 2024年 / 12卷
关键词
Dolutegravir; integrase inhibitors; weight gain; HIV; metabolic comorbidities; TENOFOVIR DISOPROXIL FUMARATE; ANTIRETROVIRAL-NAIVE ADULTS; ONCE-DAILY DOLUTEGRAVIR; SEXUAL-DIMORPHISM; HIV-INFECTION; EFAVIRENZ; THERAPY; OBESITY; LEPTIN; PHARMACOGENETICS;
D O I
10.1177/20503121241260613
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations. Excessive weight gain associated with dolutegravir-based regimens is an emerging issue; however, the long-term metabolic consequences of this effect have not been fully understood. Growing evidence shows that this leads to a higher incidence of hyperglycemia, hypertension, and metabolic syndrome, along with elevated cardiovascular risk. Dolutegravir-based regimens, also associated with greater adipocyte differentiation and greater expression of markers associated with lipid storage, continue to be a problem among patients living with human immunodeficiency virus. The mechanisms by which certain antiretroviral therapy agents differentially contribute to weight gain remain unknown. Some clinical investigators speculate that dolutegravir could interfere with central nervous system appetite regulation (melanocortin-4 receptor) and insulin signaling, or may have better penetration of adipose tissue where they could exert a direct impact on adipose tissue adipogenesis, fibrosis, and insulin resistance. This review summarizes our current understanding of weight gain and fat changes associated with dolutegravir and its possible secondary metabolic comorbidities.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Treatment of clozapine-associated weight gain: a systematic review
    Z. Whitney
    R. M. Procyshyn
    D. H. Fredrikson
    A. M. Barr
    European Journal of Clinical Pharmacology, 2015, 71 : 389 - 401
  • [32] Weight gain associated with taking psychotropic medication: An integrative review
    McCloughen, Andrea
    Foster, Kim
    INTERNATIONAL JOURNAL OF MENTAL HEALTH NURSING, 2011, 20 (03) : 202 - 222
  • [33] Weight gain over 3 kg is associated with worse metabolic syndrome indicators, regardless of weight gain recognition in Japanese workers
    Toga, Shiori
    Fukkoshi, Yuko
    Akamatsu, Rie
    JOURNAL OF HEALTH PSYCHOLOGY, 2018, 23 (13) : 1711 - 1719
  • [34] Excess gestational weight gain (GWG) is associated with alterations in metabolic function of the microbiome
    Antony, Kathleen
    Ma, Jun
    Mitchell, Kristen
    Racusin, Diana
    Petrosino, Joseph
    Versalovic, James
    Aagaard, Kjersti
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2014, 210 (01) : S45 - S46
  • [35] A low resting metabolic rate in late childhood is associated with weight gain in adolescence
    Hohenadel, Maximilian G.
    Hollstein, Tim
    Thearle, Marie
    Reinhardt, Martin
    Piaggi, Paolo
    Salbe, Arline D.
    Krakoff, Jonathan
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 93 : 68 - 74
  • [37] Metabolic Syndrome and Weight Gain in Adulthood
    Alley, Dawn E.
    Chang, Virginia W.
    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2010, 65 (01): : 111 - 117
  • [38] Metabolic Determinants of Weight Gain in Humans
    Piaggi, Paolo
    OBESITY, 2019, 27 (05) : 691 - 699
  • [39] Weight gain among HIV-positive persons treated with dolutegravir or elvitegravir
    Belkhir, L.
    Vincent, A.
    De Greef, J.
    Yombi, J. C.
    Vandercam, B.
    HIV MEDICINE, 2019, 20 : 277 - 277
  • [40] REVISION OF PRIOR ROUX-EN-Y GASTRIC BYPASS FOR RECURRENT WEIGHT GAIN WITH ASSOCIATED COMORBIDITIES
    Geva, A.
    Sonnanstine, T.
    OBESITY SURGERY, 2018, 28 : 23 - 23